ライフサイエンスコーパス: clinical development

1 t for antibiotics and many inhibitors are in clinical development.

2 ights multiple new drivers as candidates for clinical development.

3 bility that it might be a good candidate for clinical development.

4 parallel without impacting the rapid path to clinical development.

5 rase basic protein 2) inhibitor currently in clinical development.

6 so refer to the molecules in preclinical and clinical development.

7 are being investigated in various stages of clinical development.

8 ract infection, thereby supporting continued clinical development.

9 ity to trans fats and to PORCN inhibitors in clinical development.

10 EBV infection should be further explored for clinical development.

11 ced anti-RLN2 Abs in patients, hampering its clinical development.

12 e HSF1 inhibitors as chemical probes and for clinical development.

13 oval and many more are at advanced stages of clinical development.

14 is a new type of beta-lactamase inhibitor in clinical development.

15 knowledge, the first KRAS(G12C) inhibitor in clinical development.

16 ecule inhibitor of type I PRMTs currently in clinical development.

17 ell therapy and laid a foundation for future clinical development.

18 cific pathways and immune checkpoints are in clinical development.

19 ent, 2 bsAbs are marketed and over 85 are in clinical development.

20 BVM, leading to the discontinuation of BVM's clinical development.

21 in cancer cells is crucial to their further clinical development.

22 molecule inhibitors of MDM2 are currently in clinical development.

23 tors of its interaction with NRF2 are now in clinical development.

24 oadly neutralizing antibodies (bNAbs) are in clinical development.

25 enicity profile, holding promise for further clinical development.

26 han 150 peptide therapeutics are globally in clinical development.

27 y low oral bioavailability limit its further clinical development.

28 gree of protection and should be advanced in clinical development.

29 s an area in which biomarkers are needed for clinical development.

30 f TPPs is critical for their preclinical and clinical development.

31 erapeutic use and hundreds more currently in clinical development.

32 ase (PI3K)-delta/gamma isoforms currently in clinical development.

33 makes it an excellent candidate for further clinical development.

34 foliglurax) was nominated as a candidate for clinical development.

35 ory AML and have informed subsequent phase 2 clinical development.

36 by use of structural information that are in clinical development.

37 tion presents additional challenges to their clinical development.

38 trials can be used to improve pediatric SLIT clinical development.

39 be safe and immunogenic and is available for clinical development.

40 ass" small-molecule LOXL2 inhibitor to enter clinical development.

41 in clinical trials, with many others in pre-clinical development.

42 duction is complex and poses an obstacle for clinical development.

43 tion of JNJ-54175446 (14) as a candidate for clinical development.

44 therapeutic approaches based on this are in clinical development.

45 clinical trials, and many more are in early clinical development.

46 ing cancer, and several MT inhibitors are in clinical development.

47 ld be considered for further preclinical and clinical development.

48 AS(G12C) to identify inhibitors suitable for clinical development.

49 Several new oral compounds are in late-stage clinical development.

50 thritis, and further agents are currently in clinical development.

51 are being expedited through preclinical and clinical development.

52 lecules, CT7001 and SY-1365, currently under clinical development.

53 l NLRP3 inflammasome inhibitors currently in clinical development.

54 first small-molecule CD73 inhibitor to enter clinical development.

55 lites, completed only once compounds entered clinical development.

56 n be exploited as mechanistic probes and for clinical development.

57 an kidney) that provides a basis for further clinical development.

58 1 modulators that have potential for further clinical development.

59 n-spectrum beta-lactamase inhibitor to enter clinical development.

60 and DNA damage in HGSOC, warranting further clinical development.

61 xic and/or ototoxic, which has limited their clinical development.

62 efficacy in various cancer models, and their clinical development.

63 candidate nomination and then refined during clinical development.

64 of achieving therapeutic exposures in early clinical development.

65 ain an active area of research focus and pre-clinical development.

66 significant antitumor activity that supports clinical development.

67 is fundamental knowledge might inform future clinical developments.

68 logs, their mechanisms of actions, and their clinical developments.

69 lizing activity of 9 anti-HIV-1 bNAbs now in clinical development against 126 Clade A, C, D PBMC-deri

70 ation or replacement strategies currently in clinical development all require parenteral drug adminis

71 is Review covers the fundamental properties, clinical development and associated challenges of RPT.

72 he epigenetic modulatory agents currently in clinical development and discuss the opportunities and c

73 -SEB Ab GC132a is an excellent candidate for clinical development and for bsAb engineering.

74 describe the challenges associated with the clinical development and implementation of AI platforms

75 s should be included in tuberculosis vaccine clinical development and implementation planning.

76 these novel virus-based tools has completed clinical development and is poised to make an impact on

77 iew of the regulatory considerations for the clinical development and licensure of Zika vaccine candi

78 For the continuing clinical development and long-term success of theranosti

79 p21-activated kinase (PAK) are in late-stage clinical development and might impede oncogenic signalin

80 review is to give a basic overview of OVs in clinical development and provide a description of the cu

81 However, the clinical development and regulatory evaluation of these

82 This challenge impacts both clinical development and the interpretation of chemical

83 tors resulting in several compounds entering clinical development and two FDA approved NMEs.

84 nimally invasive technique could advance the clinical development and use of genotype-directed therap

85 In this Review, we discuss clinical developments and controversies in the treatment

86 n schistosomiasis are in different phases of clinical development, and a fourth is expected to enter

87 ortant implications for vaccine delivery and clinical development, and provides a model for defining

88 rected at epigenetic modulators have entered clinical development, and results from these trials are

89 tion to better design molecules, guide their clinical development, and underwrite patient safety.

90 tate of BET inhibitor biology in relation to clinical development, and we discuss the next wave of br

91 ine candidates that are currently undergoing clinical development are highlighted.

92 The antibacterial agents currently in clinical development are predominantly derivatives of we

93 all mAbs and mAb cocktails that have entered clinical development are specific for a single member of

94 considered potentially suitable for further clinical development, are presented in this report; data

95 ical characteristics of RGLS4326 support its clinical development as a disease-modifying treatment fo

96 phatidylinositol 4-kinase inhibitor to reach clinical development as a new antimalarial.

97 JR11 is under clinical development as a PET imaging agent when labeled

98 This cocrystal form was advanced to clinical development as a potential first-in-class D1 PA

99 MEAN is a promising candidate for clinical development as a single-agent therapy or in com

100 activity of artefenomel supports its further clinical development as a treatment for P. vivax malaria

101 e first pseudokinase-directed therapeutic in clinical development as an oral treatment for autoimmune

102 actic acid) ester taxane prodrugs are in pre-clinical development as novel drug combinations and immu

103 onal antibodies are promising candidates for clinical development as potential therapeutic and/or pro

104 The discovery of the clinical development candidate MRTX849 as a potent, sele

105 SC81458 and the clinical development candidate, SC83288, are fast-acting

106 The data merit 83 as a clinical development candidate.

107 romising step toward the identification of a clinical development candidate.

108 T in various neurological diseases alongside clinical development challenges will be presented.

109 glucagon-like peptide-1 (GLP-1) analogue in clinical development, compared with insulin glargine in

110 ity and oral bioavailability resulted in the clinical development compound 46 (ABBV-744).

111 This assessment led to the nomination of the clinical development compound M8891, which is currently

112 Ag and several therapeutic strategies are in clinical development designed to pharmacologically reduc

113 ce marine-derived natural product that is in clinical development directed at HIV/AIDS eradication, c

114 r, none of them reached an advanced phase of clinical development due mainly to side effects on the C

115 approved DBOs (e.g., relebactam) or those in clinical development (e.g., nacubactam and zidebactam) p

116 Although initial preclinical and clinical development efforts focused on pharmacological

117 PI3Kalpha inhibitors, now in late-stage clinical development, elicit a robust compensatory incre

118 ures, refined the lead candidate for further clinical development, examined their safety profiles, de

119 new generation of complement inhibitors into clinical development for a variety of indications.

120 catinib, a Fyn kinase inhibitor currently in clinical development for AD treatment, was administered

121 ly, mAChR allosteric modulators have entered clinical development for Alzheimer's disease (AD) and sc

122 ther indications, with four candidates under clinical development for attention deficit hyperactivity

123 ivated DNA-crosslinking prodrug currently in clinical development for cancer therapy.

124 ta (PI3K-delta) and PI3K-gamma in late-stage clinical development for hematologic malignancy treatmen

125 el integrase inhibitor currently in advanced clinical development for HIV prevention and treatment.

126 Liver-derived stem cells are in clinical development for inborn and acquired liver disea

127 r antiprotozoal chemical scaffolds under pre-clinical development for neglected tropical diseases for

128 ys)-Pro-d-Arg-NEt(2)) have been selected for clinical development for nocturia.

129 Compounds in clinical development for nonalcoholic steatohepatitis (N

130 cancer chemotherapy while many others are in clinical development for oncology as well as other thera

131 BET family bromodomain inhibitors under clinical development for oncology bind to each of the ei

132 ibitor cabotegravir (CAB-LA) is currently in clinical development for PrEP.

133 excellent candidates for further preclinical/clinical development for prophylactic and therapeutic ap

134 Numerous interventions are in clinical development for respiratory syncytial virus (RS

135 CC-220 (compound 6), a cereblon modulator in clinical development for systemic lupus erythematosis an

136 inhibiting dye shows promise for further pre-clinical development for targeting high risk AML.

137 al antibody to MK-1654 which is currently in clinical development for the prevention of RSV infection

138 ive therapeutic KRAS cEt-ASO currently under clinical development for the treatment of cancer.

139 molecule agonist of toll-like receptor 8 in clinical development for the treatment of chronic hepati

140 MK-7655, in combination with imipenem, is in clinical development for the treatment of infections cau

141 DAS181, an inhaled sialidase, is undergoing clinical development for the treatment of PIV in adults

142 a fourth-generation cephalosporin, is under clinical development for the treatment of serious Gram-n

143 m of MDM2 by small molecules and peptides in clinical development for treatment of cancer patients wa

144 f whom survived, and is currently in Phase 2 clinical development for treatment of Ebola virus diseas

145 ned-release (SR)-Exenatide formulation under clinical development for treatment of neurodegenerative

146 rse transcriptase translocation inhibitor in clinical development for treatment of people with HIV-1

147 ariant of SRK-015P, SRK-015, is currently in clinical development for treatment of SMA.

148 neral principles guiding the nonclinical and clinical development for Zika vaccines are the same as t

149 hibition properties that has reached phase 3 clinical development, for the treatment of COVID-19.

150 ng disorder hemophilia that are currently in clinical development, gene therapy holds the promise of

151 s potential as an ideal scaffold towards pre-clinical development, given its potency against human an

152 The clinical development harnessing the antitumor potential

153 Their clinical development has not progressed because of conce

154 Several CSC inhibitors in clinical development have shown promise, either as mono-

155 non-cleavable', the vast majority of ADCs in clinical development have specific release mechanisms to

156 disposition properties before nomination to clinical development, have led to maximizing the probabi

157 Inhibitors targeting MCL1 are in clinical development, however numerous cancer models are

158 Using two compounds currently in clinical development, idasanutlin (MDM2-specific) and AT

159 Balovaptan entered phase 3 clinical development in August 2018.

160 ompound has been selected as a candidate for clinical development in hematologic malignancies, solid

161 s seem an effective drug combination for pre-clinical development in highly aggressive NSCLC.

162 atinib as an attractive strategy for further clinical development in lymphomas.

163 -positive breast cancer and are currently in clinical development in melanoma, a tumor that exhibits

164 S1P1 modulator that is currently in advanced clinical development in multiple sclerosis, was equipote

165 f BYL719, a PI3Kalpha inhibitor currently in clinical development in solid tumours.

166 epresents an exciting potential strategy for clinical development in the future.

167 intra-articular treatments are currently in clinical development in the United States, including sma

168 induced by CX-5461 is critical for rational clinical development in these patients.

169 -based lung cancer screening and discuss the clinical developments in high-risk populations worldwide

170 Despite significant scientific and clinical developments in research on several other virus

171 Current strategies in preclinical and clinical development include adoptive transfer therapies

172 New PrEP agents in clinical development include novel oral agents (eg, teno

173 ntreated advanced melanoma led to subsequent clinical development, including randomized trials.

174 hora of new cancer immunotherapies are under clinical development individually and in combination for

175 alaria vaccine candidates in preclinical and clinical development is limited.

176 erstanding the biology of HNO and furthering clinical development is the quantification and real-time

177 Further clinical development is warranted.

178 ients, at specialized centers, or is further clinical development justified, with the aim of offering

179 Disease-modifying therapies in clinical development may decrease symptoms and findings

180 rapeutics that are either FDA-approved or in clinical development, methods that suppress APA inductio

181 les targeting Na(V)1.7 have been advanced to clinical development, no Na(V)1.7-selective compound has

182 umber of Hsp90 inhibitors are in preclinical/clinical development, none strongly differentiate betwee

183 These results support further clinical development of (18)F-MK-6240 for potential appl

184 (225) Ac chelation that will facilitate the clinical development of (225) Ac TAT for the treatment o

185 PBMCs stimulated with (R)-7, supporting the clinical development of (R)-7 for the treatment of CHB.

186 d providing the molecular basis to guide pre-clinical development of 3E10 as an anti-cancer agent.

187 This data further supports the clinical development of ABA in the treatment of pre-diab

188 Clinical development of any PrP-reducing therapeutic wil

189 ety and pharmacodynamic data support further clinical development of ASP4345 for the treatment of CIA

190 a preclinical mechanistic rationale for the clinical development of Axl inhibitors to improve the tr

191 a preclinical mechanistic rationale for the clinical development of AXL inhibitors to improve the tr

192 ion in ATM-deficient models, and support the clinical development of AZD6738 in combination with olap

193 These findings support the clinical development of B7-H3.CAR-Ts.

194 to alleviate the challenges associated with clinical development of biomarker panels.

195 hese findings provide a solid foundation for clinical development of broadly protective immunotherape

196 Clinical development of catechol-based orthosteric agoni

197 e in neonatal rats; thus, the study supports clinical development of CDC-9 for oral or parenteral vac

198 effects posing significant challenges to the clinical development of CDK8/19 inhibitors.

199 variable, but their manifestation slowed the clinical development of cell replacement therapies.

200 of TNBC, and provides a strong rationale for clinical development of combination therapy with BYL719

201 expected neuroretinal dysfunction before the clinical development of diabetic retinopathy.

202 Our findings should be considered in the clinical development of drugs targeting the cytochrome b

203 t the emerging pharmacological rationale and clinical development of dual-pathway inhibition strategi

204 The clinical development of effective cancer immunotherapies

205 hese data provide proof-of-principle for the clinical development of EP300-specific inhibitors in FL

206 ur findings provide rationale supporting the clinical development of FAK inhibitors in combination wi

207 very of powerful genetic targets has spurred clinical development of gene therapy approaches to treat

208 ty, toxicity and efficacy data supportive of clinical development of genome editing to treat SCID-Xl.

209 The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1)

210 al cancer and also have implications for the clinical development of highly selective EBP inhibitors.

211 These findings encourage the clinical development of HSP90(i) + MEK(i) combination th

212 r, several safety concerns have hindered the clinical development of ibogaine, including its toxicity

213 s a central and controversial unknown in the clinical development of immunotherapeutics.

214 Herein, we compare and contrast the clinical development of immunotherapy and oncogene-direc

215 Clinical development of KCP, however, is precluded by it

216 ave established a versatile platform for the clinical development of live attenuated HCMV-vectored va

217 These results support the clinical development of liver-directed AAV gene therapy

218 To support clinical development of LRRK2 inhibitors as disease-modi

219 ings provide a preclinical rationale for the clinical development of MALT1 inhibitors in CLL, in part

220 fy pharmacodynamic biomarkers to support the clinical development of MCT inhibitors now in clinical t

221 cial therapeutic index and support continued clinical development of ME-344.

222 Clinical development of Met-targeted antibodies has been

223 However, clinical development of metronomic chemotherapy has been

224 or types, suggesting a broad opportunity for clinical development of MM-131.

225 However, clinical development of nanoparticles is challenging bec

226 tion of peripheral neuropathy as part of the clinical development of Notch pathway-modulating therape

227 The clinical development of novel ICPIs continues at a rapid

228 ysiological basis, mechanisms of action, and clinical development of novel pharmacological strategies

229 Clinical development of NTSR1 agonists has, however, bee

230 ns made in phase III clinical trials and the clinical development of omadacycline.

231 arrying large transgenes and support further clinical development of oncolytic VSV recombinants as sa

232 Clinical development of OVs is increasingly focused on t

233 nge of diseases, fostering the discovery and clinical development of peptide drugs.

234 In conclusion, our findings support clinical development of PLK1 inhibitors in patients with

235 ese data support the further preclinical and clinical development of prophylactic HSV-2 vaccines that

236 sk of abnormalities in iPSCs and will inform clinical development of reprogramming technology.

237 ibiotics, and our findings support continued clinical development of ribaxamase to prevent C difficil

238 action and a distinct chemotype support the clinical development of SC83288, as an intravenous appli

239 orm mechanism-based approaches to the future clinical development of splicing modulators in cancer tr

240 ween immune cells and cancer have led to the clinical development of strategies that redirect the pow

241 atrial fibrillation to pave the way for the clinical development of stratified atrial fibrillation t

242 tified over 30 years ago, but the successful clinical development of targeted therapies has only rece

243 the genomic drivers of cancer has led to the clinical development of targeted therapies that strike a

244 Clinical development of the centrally acting CB1 inverse

245 or RSV inhibitors, the current status of the clinical development of the compound is discussed.

246 medicinal chemistry discovery and the early clinical development of the FLAP inhibitor AZD5718 (12).

247 This supports clinical development of the vaccine to protect groups at

248 ide an update on the progress to date in the clinical development of therapeutics targeting the Notch

249 nd nucleic acid ligands critically limit the clinical development of these constructs.

250 ity of N6-LS in vivo, supporting the further clinical development of this antibody.IMPORTANCE Monoclo

251 re believed to play an important role in the clinical development of this disease.

252 sive MRSA infections and support the further clinical development of this effective therapeutic appro

253 These findings support continued clinical development of this potential therapeutic vacci

254 ell culture and in animal models, supporting clinical development of this synthetically lethal combin

255 prior data) from trials conducted during the clinical development of timothy grass SLIT-tablets.

256 However, clinical development of TNKS-specific PARP catalytic inh

257 We review the technological basis and the clinical development of total marrow irradiation and tot

258 nhancement (TE) remains contentious, but the clinical development of transmission-blocking vaccines b

259 These data support the rationale for clinical development of TTK inhibition as a radiosensiti

260 Despite initial signs of efficacy, clinical development of urelumab has been hampered by in

261 ill be a particularly useful platform in the clinical development of viral vectors expressing problem

262 ment of bone metastases and with the ongoing clinical development of, among others, (177)Lu-dodecanet

263 tudy, we analyze the causes of one hurdle to clinical development, off-target reactivity, or nonspeci

264 IPI-549, the only PI3K-gamma inhibitor in clinical development, offers a unique approach to enhanc

265 Our data therefore highlight clinical development opportunities for both ATR and WEE1

266 are used as a regulatory tool for dialog on clinical development or manufacturing plans.

267 ories of compounds that have progressed into clinical development or that have revealed new structura

268 es that have been approved or have undergone clinical development, or have significant preclinical pr

269 rculating cell-free tumor DNA correlate with clinical development over time.

270 somiasis vaccines in different phases of the clinical development pipeline and highlight the Sm-p80-b

271 from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (S

272 how evidence generated from the mepolizumab clinical development program showed that blood eosinophi

273 Clinical development programmes have focused exclusively

274 g efficacy on exacerbations are done late in clinical development programmes.

275 reatment, and accelerate the productivity of clinical development programmes.

276 is article briefly describes the background, clinical development, regulatory approach, and regulator

277 or predictive biomarker testing was based on clinical development restricted to biomarker-positive pa

278 ata package required to move a compound into clinical development safely.

279 allosteric binding sites, and summarizes the clinical development status of various compounds.

280 nhibitor mechanisms may guide differentiated clinical development strategies aimed at exploiting spec

281 Nevertheless, definition of clinical development strategies to enable sound regulato

282 markers of response support a differentiated clinical development strategy.

283 unotherapeutic strategies in preclinical and clinical development such as adoptive NK cell transfer,

284 allosteric ABL1 inhibitor that is undergoing clinical development testing in patients with CML and Ph

285 otein degrader and the first CELMoD to enter clinical development that was specifically designed for

286 During clinical development, the CS activity was chosen as a su

287 k and the ban of hydroxamate inhibitors from clinical development, the discovery of non-hydroxamate m

288 OX40 agonists are in clinical development to enhance antitumor immune respons

289 uses a first-in-class PDI inhibitor entering clinical development to enhance the effects of epigeneti

290 the two H5 pLAIV candidates are suitable for clinical development to protect humans from infection wi

291 onal antibodies (mAbs) are in industrial and clinical development to treat myriad diseases.

292 ovel siderophore cephalosporin in late-stage clinical development, utilizes a "Trojan horse" active t

293 quently considered as its "ancestor" and OBZ clinical development was justified by the importance of

294 The selection of anti-HIV-1 bNAbs for clinical development was primarily guided by their in vi

295 d anticancer drugs or compounds currently in clinical development, we set out to identify novel effec

296 dation in circulation are major problems for clinical development, we studied the mechanism ATRAM use

297 BANDIT to ONC201-an anti-cancer compound in clinical development whose target had remained elusive.

298 . administered, yeast beta-1,3/1,6 glucan in clinical development with checkpoint inhibitors.

299 linic or currently under active research and clinical development, with particular emphasis on their

300 xon 14 skipping alterations are currently in clinical development, with promising data available from